|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: NOL7 |
Gene summary for NOL7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | NOL7 | Gene ID | 51406 |
| Gene name | nucleolar protein 7 | |
| Gene Alias | C6orf90 | |
| Cytomap | 6p23 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | A0A024QZW2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51406 | NOL7 | HTA11_1938_2000001011 | Human | Colorectum | AD | 1.49e-05 | 3.07e-01 | -0.0811 |
| 51406 | NOL7 | HTA11_78_2000001011 | Human | Colorectum | AD | 1.13e-03 | 2.65e-01 | -0.1088 |
| 51406 | NOL7 | HTA11_347_2000001011 | Human | Colorectum | AD | 7.67e-20 | 4.41e-01 | -0.1954 |
| 51406 | NOL7 | HTA11_83_2000001011 | Human | Colorectum | SER | 1.58e-03 | 2.48e-01 | -0.1526 |
| 51406 | NOL7 | HTA11_696_2000001011 | Human | Colorectum | AD | 1.61e-02 | 2.09e-01 | -0.1464 |
| 51406 | NOL7 | HTA11_866_2000001011 | Human | Colorectum | AD | 6.47e-05 | 2.00e-01 | -0.1001 |
| 51406 | NOL7 | HTA11_1391_2000001011 | Human | Colorectum | AD | 4.18e-13 | 4.09e-01 | -0.059 |
| 51406 | NOL7 | HTA11_2992_2000001011 | Human | Colorectum | SER | 3.54e-02 | 3.26e-01 | -0.1706 |
| 51406 | NOL7 | HTA11_5212_2000001011 | Human | Colorectum | AD | 6.46e-04 | 3.47e-01 | -0.2061 |
| 51406 | NOL7 | HTA11_5216_2000001011 | Human | Colorectum | SER | 3.12e-02 | 3.41e-01 | -0.1462 |
| 51406 | NOL7 | HTA11_866_3004761011 | Human | Colorectum | AD | 2.34e-13 | 3.31e-01 | 0.096 |
| 51406 | NOL7 | HTA11_6801_2000001011 | Human | Colorectum | SER | 2.21e-05 | 4.48e-01 | 0.0171 |
| 51406 | NOL7 | HTA11_7696_3000711011 | Human | Colorectum | AD | 5.37e-03 | 1.84e-01 | 0.0674 |
| 51406 | NOL7 | HTA11_6818_2000001021 | Human | Colorectum | AD | 1.32e-02 | 2.37e-01 | 0.0588 |
| 51406 | NOL7 | HTA11_99999970781_79442 | Human | Colorectum | MSS | 7.32e-11 | 3.45e-01 | 0.294 |
| 51406 | NOL7 | HTA11_99999965062_69753 | Human | Colorectum | MSI-H | 1.88e-02 | 6.91e-01 | 0.3487 |
| 51406 | NOL7 | HTA11_99999965104_69814 | Human | Colorectum | MSS | 7.82e-07 | 3.91e-01 | 0.281 |
| 51406 | NOL7 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 5.81e-13 | 4.44e-01 | 0.3859 |
| 51406 | NOL7 | HTA11_99999973899_84307 | Human | Colorectum | MSS | 3.38e-07 | 3.12e-01 | 0.2585 |
| 51406 | NOL7 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 3.94e-04 | 2.22e-01 | 0.3005 |
| Page: 1 2 3 4 5 6 7 8 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| NOL7 | deletion | Frame_Shift_Del | rs776624076 | c.707delN | p.Lys238AsnfsTer16 | p.K238Nfs*16 | Q9UMY1 | protein_coding | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| NOL7 | SNV | Missense_Mutation | rs201177610 | c.9N>T | p.Gln3His | p.Q3H | Q9UMY1 | protein_coding | deleterious_low_confidence(0.01) | benign(0.205) | TCGA-EK-A2PG-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
| NOL7 | insertion | Frame_Shift_Ins | rs544905440 | c.706_707insA | p.Gln239ThrfsTer7 | p.Q239Tfs*7 | Q9UMY1 | protein_coding | TCGA-A6-2672-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| NOL7 | deletion | Frame_Shift_Del | c.716delN | p.Asn240MetfsTer14 | p.N240Mfs*14 | Q9UMY1 | protein_coding | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |||
| NOL7 | deletion | Frame_Shift_Del | rs776624076 | c.707delN | p.Lys238AsnfsTer16 | p.K238Nfs*16 | Q9UMY1 | protein_coding | TCGA-AA-3715-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | ||
| NOL7 | insertion | Frame_Shift_Ins | rs544905440 | c.706_707insA | p.Gln239ThrfsTer7 | p.Q239Tfs*7 | Q9UMY1 | protein_coding | TCGA-AA-A01P-01 | Colorectum | colon adenocarcinoma | Female | >=65 | III/IV | Unknown | Unknown | PD | ||
| NOL7 | insertion | Frame_Shift_Ins | rs544905440 | c.706_707insA | p.Gln239ThrfsTer7 | p.Q239Tfs*7 | Q9UMY1 | protein_coding | TCGA-AZ-6598-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| NOL7 | SNV | Missense_Mutation | novel | c.340C>A | p.Leu114Ile | p.L114I | Q9UMY1 | protein_coding | deleterious(0) | probably_damaging(0.987) | TCGA-AP-A1E0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| NOL7 | SNV | Missense_Mutation | c.483N>C | p.Gln161His | p.Q161H | Q9UMY1 | protein_coding | deleterious(0.01) | benign(0.248) | TCGA-AX-A0J0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| NOL7 | SNV | Missense_Mutation | novel | c.565N>A | p.Ala189Thr | p.A189T | Q9UMY1 | protein_coding | tolerated(0.13) | benign(0.241) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |